---
schema_version: "secwatch.filing_event.v1"
accession: "0001650664-26-000043"
form_type: "8-K"
ticker: "EDIT"
cik: "0001650664"
company_name: "Editas Medicine, Inc."
filed_at: "2026-05-05T23:59:59+00:00"
generated_at: "2026-05-14T23:24:38.822515+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Editas Q1 net loss $25M ($0.26/share); EDIT-401 on track for human data by year-end

## Summary
- Net loss of $25.0M ($0.26 per share) vs. $76.1M ($0.92) in Q1 2025; no restructuring charges this quarter.
- Cash and equivalents $123.6M as of March 31; expected to fund operations into Q3 2027.
- R&D expenses down 34% YoY to $17.6M due to reni-cel discontinuation and headcount reduction.
- EDIT-401 preclinical shows >90% mean LDL-C reduction; first-in-human trial for HeFH expected in H2 2026 with proof-of-concept data by year-end.
- USPTO reaffirmed Broad Institute's priority in CRISPR/Cas9 patent interference, supporting Editas' licensed IP.

## SEC filing metadata
- accession: 0001650664-26-000043
- form_type: 8-K
- ticker: EDIT
- cik: 0001650664
- company_name: Editas Medicine, Inc.
- filed_at: 2026-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650664/000165066426000043/0001650664-26-000043-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650664/000165066426000043/edit-20260505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001650664-26-000043
- JSON: https://secwatch.observer/filing/0001650664-26-000043.json
- Plain text: https://secwatch.observer/filing/0001650664-26-000043.txt

## Source-grounded claims
- claim_id: 117f747aeccd76fb31214a8909ac410f881a3eee
  claim: Editas Medicine, Inc. reported the first quarter 2026 results: net income net loss attributable to common stockholders was $25.0 million , or $0.26 per share.
  evidence_excerpt: expenditure requirements into the third quarter of 2027. First Quarter 2026 • For the three months ended March 31, 2026 , net loss attributable to common stockholders was $25.0 million , or $0.26 per share, compared to net loss of $76.1 million , or $0.92 per share, for the same period in 2025 . • Collaboration and other research and development revenues
  evidence_url: https://www.sec.gov/Archives/edgar/data/1650664/000165066426000043/0001650664-26-000043-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.